GlaxoSmithKline PLC ADR
I · Análisis con IA
En breve
GSK develops and sells vaccines for diseases like RSV, shingles, flu, and HPV, plus specialty treatments for cancer, HIV, and respiratory conditions, and everyday medicines for asthma and infections [COMPANY OVERVIEW]. The company operates globally with manufacturing and research facilities, selling through hospitals, clinics, and pharmacies in over 100 countries. GSK also collaborates with partners like CureVac on mRNA vaccine technology and AN2 Therapeutics on tuberculosis therapies [COMPANY OVERVIEW].
GSK is a major UK-headquartered pharmaceutical company that makes vaccines (RSV, flu, shingles, meningitis), specialty medicines (oncology, HIV, respiratory), and general medicines (asthma, COPD, antibiotics) [COMPANY OVERVIEW]. With $32,7 billion in revenue and a 17,5% net margin, the company is financially healthy and generates $5,8 billion in free cash flow annually [Yahoo Finance]. Recent news shows Japan expanded approval for GSK's RSV vaccine Arexvy to younger at-risk adults, opening a larger market [Nasdaq].
GSK is financially strong with solid profitability, low debt, and healthy cash generation.
Puntuación Sentinellis
7,9/10
Financieramente sana
Capitalización bursátil
$102,4B
Ingresos (12 meses)
GBP 32,7B
Explicaciones
Cómo leemos estas cifras
Guías en lenguaje sencillo · sin cuenta
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LeerPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LeerAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LeerII · Noticias recientes
Qué movió el precio
1 noticia · ordenadas por relevancia
- Macro2026-05-18
GSK: Japan's MHLW Expands Eligible Population For Arexvy
Nasdaq
Premium · gratis con cualquier cuenta
Dodge & Cox, the second-largest institutional holder at 2,92% of the company, cut its stake by 14,4% in the most recent quarter, a meaningful reduction that could signal concerns about near-term performance or valuation [EODHD].
Riesgos
4
Oportunidades
4
Señales de alerta
1
Dirección
10
8 hallazgos más en el informe completo — gratis con cualquier cuenta.
Desbloquea el análisis completo de GlaxoSmithKline PLC ADR
Crea una cuenta gratuita para acceder al informe completo generado con IA, con fuentes citadas en el texto.
- 4 riesgos, 4 oportunidades y 1 señal de alerta — cada uno con su fuente
- Más de 100 métricas financieras con gráficos y comparativas
- Resúmenes completos de noticias con enlaces a las fuentes
- Equipo directivo y remuneración
III · Empresas similares
También te puede interesar
Mismo sector · Salud — o salud financiera comparable
¿La añades a tu lista?